AskBio bails on in-licensed gene therapy program after finding issues with 3rd-party manufacturer
Managing a co-developed drug isn’t easy, particularly when you add a third-party manufacturing partner into the mix. Now, AskBio will hit the exits on a licensing deal with Selecta for gene therapy program MMA-101 after finding fault with a contract manufacturer’s work.
Now in full ownership of its methylmalonic acidemia (MMA) program, Selecta has delayed filing an IND until at least Q4 after identifying a “manufacturing issue we believe is related to a component sourced from a third-party,” the company said in a statement.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.